Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives

References

• Abbasi M , Sohail M , Minhas MU , et al. ( 2019). Novel biodegradable pH-sensitive hydrogels: An efficient controlled release system to manage ulcerative colitis. Int J Biol Macromol 136: 1–14.
   PubMed Web of Science ®Google Scholar
• Abuchowski A , McCoy JR , Palczuk NC , et al. ( 1977). Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252: 3582–6.
   PubMed Web of Science ®Google Scholar
• Aib S , Iqbal K , Khan N , et al. ( 2022). pH-sensitive liposomes for colonic co-delivery of mesalazine and curcumin for the treatment of ulcerative colitis. J Drug Delivery Sci Technol 72: 103335.
   Web of Science ®Google Scholar
• Akbarzadeh A , Samiei M , Joo SW , et al. ( 2019). Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line (Retraction of Vol 10, art no 46. BMC CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND.
   Google Scholar
• Alsaad A , Hussien AA , Gareeb MM. ( 2020). Solid lipid nanoparticles (SLN) as a novel drug delivery system: A theoretical review. Syst Rev Pharm 11: 259–73.
   Google Scholar
• Arévalo-Pérez R , Maderuelo C , Lanao JM. ( 2020). Recent advances in colon drug delivery systems. J Control Release 327: 703–24.
   PubMed Web of Science ®Google Scholar
• Aslan B , Ozpolat B , Sood AK , Lopez-Berestein G. ( 2013). Nanotechnology in cancer therapy. J Drug Target 21: 904–13.
   PubMed Web of Science ®Google Scholar
• Awad A , Madla CM , McCoubrey LE , et al. ( 2022). Clinical translation of advanced colonic drug delivery technologies. Adv Drug Delivery Rev 181: 114076.
   PubMed Web of Science ®Google Scholar
• Barea M , Jenkins M , Gaber M , Bridson R. ( 2010). Evaluation of liposomes coated with a pH responsive polymer. Int J Pharm 402: 89–94.
   PubMed Web of Science ®Google Scholar
• Barea M , Jenkins M , Lee Y , et al. ( 2012). Encapsulation of liposomes within pH responsive microspheres for oral colonic drug delivery. Int J Biomater 2012: 1–8.
   Google Scholar
• Beloqui A , Coco R , Memvanga PB , et al. ( 2014). pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm 473: 203–12.
   PubMed Web of Science ®Google Scholar
• Bertoni S , Machness A , Tiboni M , et al. ( 2020). Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting. Biopolymers 111: e23336.
   PubMed Web of Science ®Google Scholar
• Birben E , Sahiner UM , Sackesen C , et al. ( 2012). Oxidative stress and antioxidant defense. World Allergy Organ J 5: 9–19.
   PubMedGoogle Scholar
• Cantero-Recasens G , Burballa C , Ohkawa Y , et al. ( 2022). The ulcerative colitis-associated gene FUT8 regulates the quantity and quality of secreted mucins. Proc Natl Acad Sci U S A 119: e2205277119.
   PubMed Web of Science ®Google Scholar
• Caster JM , Callaghan C , Seyedin SN , et al. ( 2019). Optimizing advances in nanoparticle delivery for cancer immunotherapy. Adv Drug Deliv Rev 144: 3–15.
   PubMed Web of Science ®Google Scholar
• Chen L , Hong W , Ren W , et al. ( 2021). Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Sig Transduct Target Ther 6: 1–25.
   PubMed Web of Science ®Google Scholar
• Chen R , Lin X , Wang Q , et al. ( 2023). Dual-targeting celecoxib nanoparticles protect intestinal epithelium and regulate macrophage polarization for ulcerative colitis treatment. Chemical Engineering Journal 452: 139445.
   Web of Science ®Google Scholar
• Chen S-q , Song Y-q , Wang C , et al. ( 2020). Chitosan-modified lipid nanodrug delivery system for the targeted and responsive treatment of ulcerative colitis. Carbohydr Polym 230: 115613.
   PubMed Web of Science ®Google Scholar
• Chen Z , Farag MA , Zhong Z , et al. ( 2021). Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems. Adv Drug Deliv Rev 176: 113870.
   PubMed Web of Science ®Google Scholar
• Cherukuri S , Neelabonia V , Reddipalli S , Komaragiri K. ( 2012). A review on pharamceutical approaches on current trends of colon specific drug delivery system. Int Res J Pharm 3: 45–55.
   Google Scholar
• Claesson-Welsh L , Dejana E , McDonald DM. ( 2021). Permeability of the endothelial barrier: identifying and reconciling controversies. Trends Mol Med 27: 314–31.
   PubMed Web of Science ®Google Scholar
• Cortada CM , Gil A , Goncalves S , et al. ( 2009). P-glycoprotein functional activity in peripheral blood lymphocytes in ulcerative colitis. Medicina 69: 437–41.
   PubMed Web of Science ®Google Scholar
• Cui M , Fang Z , Song M , et al. ( 2022). Phragmites rhizoma polysaccharide-based nanocarriers for synergistic treatment of ulcerative colitis. Int J Biol Macromol 220: 22–32.
   PubMed Web of Science ®Google Scholar
• D’Amico F , Magro F , Peyrin-Biroulet L , Danese S. ( 2022). Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis 16: 835–44.
   PubMed Web of Science ®Google Scholar
• Danese S , Grisham M , Hodge J , Telliez J-B. ( 2016). JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 310: G155–G162.
   PubMed Web of Science ®Google Scholar
• Deng X-Q , Zhang H-B , Wang G-F , et al. ( 2019). Colon-specific microspheres loaded with puerarin reduce tumorigenesis and metastasis in colitis-associated colorectal cancer. Int J Pharm 570: 118644.
   PubMedGoogle Scholar
• Dev RK , Bali V , Pathak K. ( 2011). Novel microbially triggered colon specific delivery system of 5-Fluorouracil: Statistical optimization, in vitro, in vivo, cytotoxic and stability assessment. Int J Pharm 411: 142–51.
   PubMed Web of Science ®Google Scholar
• Ding C , Sun Y , Wang Y , et al. ( 2017). Adsorbent for resorcinol removal based on cellulose functionalized with magnetic poly (dopamine). Int J Biol Macromol 99: 578–85.
   PubMed Web of Science ®Google Scholar
• Donaldson GP , Lee SM , Mazmanian SK. ( 2016). Gut biogeography of the bacterial microbiota. Nat Rev Microbiol 14: 20–32.
   PubMed Web of Science ®Google Scholar
• E, Leucuta ( 2012). Drug delivery systems with modified release for systemic and biophase bioavailability. Current Clinical Pharmacology 7: 282–317.
   PubMedGoogle Scholar
• Ordás I , Eckmann L , Talamini M , et al. ( 2012). Ulcerative colitis. Lancet 380: 1606–19.
   PubMed Web of Science ®Google Scholar
• Fändriks L. ( 2017). Roles of the gut in the metabolic syndrome: an overview. J Intern Med 281: 319–36.
   PubMed Web of Science ®Google Scholar
• Feagan BG , MacDonald JK. ( 2012). Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane database of systematic reviews.(10).
   Google Scholar
• Feagan BG , Rutgeerts P , Sands BE , et al. ( 2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369: 699–710.
   PubMed Web of Science ®Google Scholar
• Frede A , Neuhaus B , Klopfleisch R , et al. ( 2016). Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo. J Control Release 222: 86–96.
   PubMed Web of Science ®Google Scholar
• Gao M , Yang C , Wu C , et al. ( 2022). Hydrogel–metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis. J Nanobiotechnol 20: 1–12.
   PubMed Web of Science ®Google Scholar
• Gaohua L , Miao X , Dou L. ( 2021). Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity. Expert Opin Drug Metab Toxicol 17: 1103–24.
   PubMed Web of Science ®Google Scholar
• Garbern JC , Minami E , Stayton PS , Murry CE. ( 2011). Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 32: 2407–16.
   PubMed Web of Science ®Google Scholar
• Gauri B , Singh SK , Mishra D. ( 2011). Formulation and evaluation of colon targeted oral drug delivery systems for metronidazole in treatment of amoebiasis. International Journal of Drug Delivery 3: 503.
   Google Scholar
• Gavhane YN , Yadav AV. ( 2012). Loss of orally administered drugs in GI tract. Saudi Pharm J 20: 331–44.
   PubMed Web of Science ®Google Scholar
• Grondin JA , Kwon YH , Far PM , et al. ( 2020). Mucins in intestinal mucosal defense and inflammation: learning from clinical and experimental studies. Front Immunol 11: 2054.
   PubMed Web of Science ®Google Scholar
• Gugulothu D , Kulkarni A , Patravale V , Dandekar P. ( 2014). pH-sensitive nanoparticles of curcumin–celecoxib combination: evaluating drug synergy in ulcerative colitis model. J Pharm Sci 103: 687–96.
   PubMed Web of Science ®Google Scholar
• Günter EA , Markov PA , Melekhin AK , et al. ( 2018). Preparation and release characteristics of mesalazine loaded calcium pectin-silica gel beads based on callus cultures pectins for colon-targeted drug delivery. Int J Biol Macromol 120: 2225–33.
   PubMed Web of Science ®Google Scholar
• Heller F , Fromm A , Gitter A , et al. ( 2008). Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. Mucosal Immunology 1: S58–S61.
   PubMed Web of Science ®Google Scholar
• Helmy AM , Elsabahy M , Abd-Elkareem M , et al. ( 2020). High-Payload chitosan microparticles for the colonic delivery of quercetin: Development and in-vivo evaluation in a rabbit colitis model. J Drug Delivery Sci Technol 58: 101832.
   Web of Science ®Google Scholar
• Hita V , Singh R , Jain SK. ( 1997). Colonic targeting of metronidazole using azo aromatic polymers: development and characterization. Drug Delivery 4: 19–22.
   Web of Science ®Google Scholar
• Hlaing SP , Cao J , Lee J , et al. ( 2022). Hyaluronic Acid-Conjugated PLGA Nanoparticles Alleviate Ulcerative Colitis via CD44-Mediated Dual Targeting to Inflamed Colitis Tissue and Macrophages. Pharmaceutics 14: 2118.
   PubMed Web of Science ®Google Scholar
• Hossen S , Hossain MK , Basher M , et al. ( 2019). Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J Adv Res 15: 1–18.
   PubMed Web of Science ®Google Scholar
• mHua S , s. ( 2014). Orally administered liposomal formulationfor colon targeted drug delivery. Frontiers Media SA. 138.
   Google Scholar
• Johnstone RW , Ruefli AA , Smyth MJ. ( 2000). Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25: 1–6.
   PubMed Web of Science ®Google Scholar
• Kadiyam R , Muzib YI. ( 2015). Colon specific drug delivery of tramadol HCl for chronotherapeutics of arthritis. Int J Pharm Investig 5: 43–9.
   PubMedGoogle Scholar
• Kaur G , Singh SK , Kumar R , et al. ( 2020). Development of modified apple polysaccharide capped silver nanoparticles loaded with mesalamine for effective treatment of ulcerative colitis. J Drug Delivery Sci Technol 60: 101980.
   Web of Science ®Google Scholar
• Kayal M , Shah S. ( 2019). Ulcerative colitis: current and emerging treatment strategies. JCM 9: 94.
   Google Scholar
• Keane TJ , Dziki J , Sobieski E , et al. ( 2017). Restoring mucosal barrier function and modifying macrophage phenotype with an extracellular matrix hydrogel: potential therapy for ulcerative colitis. Journal of Crohn’s and Colitis 11: 360–8.
   PubMed Web of Science ®Google Scholar
• Ko CW , Singh S , Feuerstein JD , et al. ( 2019). AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology 156: 748–64.
   PubMed Web of Science ®Google Scholar
• Kotla NG , Gulati M , Singh SK , Shivapooja A. ( 2014). Facts, fallacies and future of dissolution testing of polysaccharide based colon-specific drug delivery. J Control Release 178: 55–62.
   PubMed Web of Science ®Google Scholar
• Kucharzik T , Koletzko S , Kannengiesser K , Dignass A. ( 2020). Ulcerative colitis—diagnostic and therapeutic algorithms. Deutsches Ärzteblatt International 117: 564.
   PubMed Web of Science ®Google Scholar
• Kumar B , Kulanthaivel S , Mondal A , et al. ( 2017). Mesoporous silica nanoparticle based enzyme responsive system for colon specific drug delivery through guar gum capping. Colloids Surf B Biointerfaces 150: 352–61.
   PubMed Web of Science ®Google Scholar
• Lamprecht A , Yamamoto H , Takeuchi H , Kawashima Y. ( 2004). Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus. Eur J Pharm Biopharm 58: 37–43.
   PubMed Web of Science ®Google Scholar
• Lee C-M , Kim D-W , Lee H-C , Lee K-Y. ( 2004). Pectin microspheres for oral colon delivery: Preparation using spray drying method and in vitro release of indomethacin. Biotechnol Bioprocess Eng 9: 191–5.
   Web of Science ®Google Scholar
• Lee MS , Kim Y-J. ( 2007). Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 76: 447–80.
   PubMed Web of Science ®Google Scholar
• Lee Y , Sugihara K , Gillilland MG , et al. ( 2020). Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater 19: 118–26.
   PubMed Web of Science ®Google Scholar
• Lee Y , Thompson D. ( 2017). Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9: e1450.
   Web of Science ®Google Scholar
• Li S , Jin M , Wu Y , et al. ( 2021). An efficient enzyme-triggered controlled release system for colon-targeted oral delivery to combat dextran sodium sulfate (DSS)-induced colitis in mice. Drug Deliv 28: 1120–31.
   PubMed Web of Science ®Google Scholar
• Li X , Yang Y , Wang Z , et al. ( 2022). Multistage-responsive nanocomplexes attenuate ulcerative colitis by improving the accumulation and distribution of oral nucleic acid drugs in the colon. ACS Appl Mater Interfaces 14: 2058–70.
   PubMed Web of Science ®Google Scholar
• Lichtiger S , Present DH , Kornbluth A , et al. ( 1994). Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841–5.
   PubMed Web of Science ®Google Scholar
• Ling K , Wu H , Neish AS , Champion JA. ( 2019). Alginate/chitosan microparticles for gastric passage and intestinal release of therapeutic protein nanoparticles. J Control Release 295: 174–86.
   PubMed Web of Science ®Google Scholar
• Liu L , Yao W , Rao Y , et al. ( 2017). pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms. Drug Deliv 24: 569–81.
   PubMed Web of Science ®Google Scholar
• Liu P , Gao C , Chen H , et al. ( 2021). Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: opportunities and emerging strategies. Acta Pharm Sin B 11: 2798–818.
   PubMed Web of Science ®Google Scholar
• Lundquist P , Artursson P. ( 2016). Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues. Adv Drug Deliv Rev 106: 256–76.
   PubMed Web of Science ®Google Scholar
• Lynch R , Lowe D , Protheroe A , et al. ( 2013). Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther 38: 935–45.
   PubMed Web of Science ®Google Scholar
• Makhlof A , Tozuka Y , Takeuchi H. ( 2009). pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm 72: 1–8.
   PubMed Web of Science ®Google Scholar
• Mandlik DS , Mandlik SK , Patel S. ( 2021). Protective effect of sarsasapogenin in TNBS induced ulcerative colitis in rats associated with downregulation of pro-inflammatory mediators and oxidative stress. Immunopharmacol Immunotoxicol 43: 571–83.
   PubMed Web of Science ®Google Scholar
• Moghimi SM , Hunter AC , Murray JC. ( 2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53: 283–318.
   PubMed Web of Science ®Google Scholar
• Moghimi SM , Szebeni J. ( 2003). Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42: 463–78.
   PubMed Web of Science ®Google Scholar
• Mohan LJ , Daly JS , Ryan BM , Ramtoola Z. ( 2019). The future of nanomedicine in optimising the treatment of inflammatory bowel disease. Scand J Gastroenterol 54: 18–26.
   PubMed Web of Science ®Google Scholar
• Naeem M , Bae J , Oshi MA , et al. ( 2018). Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomedicine 13: 1225–40.
   PubMed Web of Science ®Google Scholar
• Naeem M , Lee J , Oshi MA , et al. ( 2020). Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. Acta Biomater 116: 368–82.
   PubMed Web of Science ®Google Scholar
• Nagpal K , Singh SK , Mishra DN. ( 2010). Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 58: 1423–30.
   PubMed Web of Science ®Google Scholar
• Naserifar M , Hosseinzadeh H , Abnous K , et al. ( 2020). Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. Life Sci 262: 118555.
   PubMed Web of Science ®Google Scholar
• Neurath MF. ( 2017). Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 14: 269–78.
   PubMed Web of Science ®Google Scholar
• Nguyen CT , Webb RI , Lambert LK , et al. ( 2017). Bifunctional succinylated ε-polylysine-coated mesoporous silica nanoparticles for pH-responsive and intracellular drug delivery targeting the colon. ACS Appl Mater Interfaces 9: 9470–83.
   PubMed Web of Science ®Google Scholar
• Ni J , Wu GD , Albenberg L , Tomov VT. ( 2017). Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 14: 573–84.
   PubMed Web of Science ®Google Scholar
• Nicholls A , Harris-Collazo R , Huang M , et al. ( 2013). Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. J Int Med Res 41: 386–94.
   PubMed Web of Science ®Google Scholar
• Niebel W , Walkenbach K , Béduneau A , et al. ( 2012). Nanoparticle-based clodronate delivery mitigates murine experimental colitis. J Control Release 160: 659–65.
   PubMed Web of Science ®Google Scholar
• Ogueri KS , Shamblin SL. ( 2022). Osmotic-controlled release oral tablets: Technology and functional insights. Trends Biotechnol 40: 606–19.
   PubMed Web of Science ®Google Scholar
• Oshi MA , Lee J , Kim J , et al. ( 2021). pH-Responsive Alginate-Based Microparticles for Colon-Targeted Delivery of Pure Cyclosporine A Crystals to Treat Ulcerative Colitis. Pharmaceutics 13: 1412.
   PubMed Web of Science ®Google Scholar
• Oshi MA , Lee J , Naeem M , et al. ( 2020). Curcumin nanocrystal/pH-responsive polyelectrolyte multilayer core–shell nanoparticles for inflammation-targeted alleviation of ulcerative colitis. Biomacromolecules 21: 3571–81.
   PubMed Web of Science ®Google Scholar
• Oshi MA , Naeem M , Bae J , et al. ( 2018). Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydr Polym 198: 434–42.
   PubMed Web of Science ®Google Scholar
• Pagnini C , Pizarro TT , Cominelli F. ( 2019). Novel pharmacological therapy in inflammatory bowel diseases: beyond anti-tumor necrosis factor. Front Pharmacol 10: 671.
   PubMed Web of Science ®Google Scholar
• Pang L , Wang T , Liao Q , et al. ( 2022). Protective role of ergothioneine isolated from Pleurotus ostreatus against dextran sulfate sodium-induced ulcerative colitis in rat model. J Food Sci 87: 415–26.
   PubMed Web of Science ®Google Scholar
• Peng C-L , Yang L-Y , Luo T-Y , et al. ( 2010). Development of pH sensitive 2-(diisopropylamino) ethyl methacrylate based nanoparticles for photodynamic therapy. Nanotechnology 21: 155103.
   PubMed Web of Science ®Google Scholar
• Peng X , Wilken SE , Lankiewicz TS , et al. ( 2021). Genomic and functional analyses of fungal and bacterial consortia that enable lignocellulose breakdown in goat gut microbiomes. Nat Microbiol 6: 499–511.
   PubMed Web of Science ®Google Scholar
• Piechota-Polanczyk A , Fichna J. ( 2014). The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol 387: 605–20.
   PubMed Web of Science ®Google Scholar
• Qi S , Luo R , Han X , et al. ( 2022). pH/ROS Dual-Sensitive Natural Polysaccharide Nanoparticles Enhance “One Stone Four Birds” Effect of Rhein on Ulcerative Colitis. ACS Appl Mater Interfaces 14: 50692–709.
   PubMed Web of Science ®Google Scholar
• Ribeiro LN , Alcântara AC , Darder M , et al. ( 2014). Pectin-coated chitosan–LDH bionanocomposite beads as potential systems for colon-targeted drug delivery. Int J Pharm 463: 1–9.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P , Sandborn WJ , Feagan BG , et al. ( 2005). Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–76.
   PubMed Web of Science ®Google Scholar
• Salvi VR , Pawar P. ( 2019). Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Delivery Sci Technol 51: 255–67.
   Web of Science ®Google Scholar
• Sandborn WJ , Feagan BG , Marano C , et al. ( 2014a). Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146: 85–95.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , Feagan BG , Marano C , et al. ( 2014b). Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146: 96–109.e1. e101.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , Su C , Sands BE , et al. ( 2017). Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376: 1723–36.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , Van Assche G , Reinisch W , et al. ( 2012). Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142: 257–65. e253.
   PubMed Web of Science ®Google Scholar
• Sardo HS , Saremnejad F , Bagheri S , et al. ( 2019). A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems. Int J Pharm 558: 367–79.
   PubMedGoogle Scholar
• Sarvar DP , Shamsasenjan K , Akbarzadehlaleh P. ( 2016). Mesenchymal stem cell-derived exosomes: new opportunity in cell-free therapy. Adv Pharm Bull 6: 293–9.
   PubMed Web of Science ®Google Scholar
• Sc T , Lj W. ( 1955). Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal 2: 1041–8.
   PubMedGoogle Scholar
• Sharif MK , Butt MS , Sharif HR. ( 2017). Role of nanotechnology in enhancing bioavailability and delivery of dietary factors. Nutrient delivery. London, United Kingdom: Elsevier; 587–618.
   Google Scholar
• Shi H , Zhao X , Gao J , et al. ( 2020). Acid-resistant ROS-responsive hyperbranched polythioether micelles for ulcerative colitis therapy. Chin Chem Lett 31: 3102–6.
   Web of Science ®Google Scholar
• Singh AK , Yadav TP , Pandey B , et al. ( 2019). Engineering nanomaterials for smart drug release: Recent advances and challenges. Applications of targeted nano drugs and delivery systems.411–49.
   Google Scholar
• Singh D , Srivastava S , Pradhan M , et al. ( 2015). Inflammatory bowel disease: pathogenesis, causative factors, issues, drug treatment strategies, and delivery approaches. Critical Reviews™ in Therapeutic Drug Carrier Systems 32:181–214.
   Web of Science ®Google Scholar
• Singh N , Khanna R. ( 2012). Colon targeted drug delivery systems-A Potential Approach. The Pharma Innovation 1:40–47.
   Google Scholar
• Sinha SR , Nguyen LP , Inayathullah M , et al. ( 2015). A thermo-sensitive delivery platform for topical administration of inflammatory bowel disease therapies. Gastroenterology 149: 52–5.e2. e52.
   PubMed Web of Science ®Google Scholar
• Soni K , Kukereja BK , Kapur M , Kohli K. ( 2015). Lipid nanoparticles: future of oral drug delivery and their current trends and regulatory issues. Int J Curr Pharm Rew Res 7: 1–8.
   Google Scholar
• Sun J , Xue P , Liu J , et al. ( 2021). Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomater Sci Eng 7: 4859–69.
   PubMed Web of Science ®Google Scholar
• Sutherland LR , MacDonald JK. ( 2006). Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews.(2).
   Google Scholar
• Talaei F , Atyabi F , Azhdarzadeh M , et al. ( 2013). Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. Eur J Pharm Sci 49: 712–22.
   PubMed Web of Science ®Google Scholar
• Tan C , Fan H , Ding J , et al. ( 2022). ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment. Mater Today Bio 14: 100246.
   PubMedGoogle Scholar
• Tang Q , Zhang W , Zhang C , et al. ( 2020). Oxymatrine loaded nitric oxide-releasing liposomes for the treatment of ulcerative colitis. Int J Pharm 586: 119617.
   PubMedGoogle Scholar
• Tao Y , Zhao X , Liu X , et al. ( 2022). Oral delivery of chitosan-coated PLGA nanoemulsion loaded with artesunate alleviates ulcerative colitis in mice. Colloids Surf B Biointerfaces 219: 112824.
   PubMed Web of Science ®Google Scholar
• Tatiya-Aphiradee N , Chatuphonprasert W , Jarukamjorn K. ( 2018). Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol 30: 1–10.
   PubMedGoogle Scholar
• Thomas S , Hoxha K , Alexander W , et al. ( 2019). Intestinal barrier tightening by a cell-penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis. J Cell Biochem 120: 4225–37.
   PubMed Web of Science ®Google Scholar
• Timmer A , Patton PH , Chande N , et al. ( 2016). Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016: CD000478.
   PubMedGoogle Scholar
• Toumi R , Samer A , Soufli I , et al. ( 2021). Role of probiotics and their metabolites in inflammatory bowel diseases (IBDs). Gastroenterology Insights 12: 56–66.
   Web of Science ®Google Scholar
• Verma S , Kumar V , Mishra D , Singh S. ( 2012). Colon targeted drug delivery: current and novel perspectives. Int J Pharm Sci Res 3: 1274.
   Google Scholar
• Vinarov Z , Abdallah M , Agundez JA , et al. ( 2021). Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. Eur J Pharm Sci 162: 105812.
   PubMed Web of Science ®Google Scholar
• Vong LB , Tomita T , Yoshitomi T , et al. ( 2012). An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice. Gastroenterology 143: 1027–36.e3. e1023.
   PubMed Web of Science ®Google Scholar
• Wan Y , Zhang B. ( 2022). The impact of zinc and zinc homeostasis on the intestinal mucosal barrier and intestinal diseases. Biomolecules 12: 900.
   PubMed Web of Science ®Google Scholar
• Wang B , Zhuang X , Deng Z-B , et al. ( 2014). Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther 22: 522–34.
   PubMed Web of Science ®Google Scholar
• Wang N , Shao L , Lu W , et al. ( 2022). 5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis. J Drug Delivery Sci Technol 74: 103578.
   Web of Science ®Google Scholar
• Wang X , Gu H , Zhang H , et al. ( 2021). Oral Core–Shell Nanoparticles Embedded in Hydrogel Microspheres for the Efficient Site-Specific Delivery of Magnolol and Enhanced Antiulcerative Colitis Therapy. ACS Appl Mater Interfaces 13: 33948–61.
   PubMed Web of Science ®Google Scholar
• Wilson DS , Dalmasso G , Wang L , et al. ( 2010). Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9: 923–8.
   PubMed Web of Science ®Google Scholar
• Xiao B , Merlin D. ( 2012). Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin Drug Deliv 9: 1393–407.
   PubMed Web of Science ®Google Scholar
• Xu H , Luo R , Dong L , et al. ( 2022). pH/ROS dual-sensitive and chondroitin sulfate wrapped poly (β-amino ester)-SA-PAPE copolymer nanoparticles for macrophage-targeted oral therapy for ulcerative colitis. Nanomedicine 39: 102461.
   PubMed Web of Science ®Google Scholar
• Xu Q , Zhang N , Qin W , et al. ( 2013). Preparation, in vitro and in vivo evaluation of budesonide loaded core/shell nanofibers as oral colonic drug delivery system. J Nanosci Nanotechnol 13: 149–56.
   PubMed Web of Science ®Google Scholar
• Xu X-R , Liu C-Q , Feng B-S , Liu Z-J. ( 2014). Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 20: 3255–64.
   PubMed Web of Science ®Google Scholar
• Yan X , Yang C , Yang M , et al. ( 2022). All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis. J Nanobiotechnol 20: 1–18.
   PubMed Web of Science ®Google Scholar
• Yang M , Lai SK , Yu T , et al. ( 2014). Nanoparticle penetration of human cervicovaginal mucus: The effect of polyvinyl alcohol. J Control Release 192: 202–8.
   PubMed Web of Science ®Google Scholar
• Yang M , Zhang Y , Ma Y , et al. ( 2020). Nanoparticle-based therapeutics of inflammatory bowel diseases: a narrative review of the current state and prospects. Journal of Bio-X Research 3: 157–73.
   Google Scholar
• Zhang C , Li J , Xiao M , et al. ( 2022). Oral colon-targeted mucoadhesive micelles with enzyme-responsive controlled release of curcumin for ulcerative colitis therapy. Chin Chem Lett 33: 4924–9.
   Web of Science ®Google Scholar
• Zhang C , Wang X , Xiao M , et al. ( 2022). Nano-in-micro alginate/chitosan hydrogel via electrospray technology for orally curcumin delivery to effectively alleviate ulcerative colitis. Materials & Design 221: 110894.
   Web of Science ®Google Scholar
• Zhang L , Zhu W , Yang C , et al. ( 2012). A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. Int J Nanomedicine 7: 151–62.
   PubMed Web of Science ®Google Scholar
• Zhang M , Viennois E , Prasad M , et al. ( 2016). Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials 101: 321–40.
   PubMed Web of Science ®Google Scholar
• Zhang M , Wang X , Han MK , et al. ( 2017). Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine (Lond) 12: 1927–43.
   PubMed Web of Science ®Google Scholar
• Zhao X-X , Ma S-B , Wen J-P , et al. ( 2022). Reactive Oxygen Species-Responsive Polyether Micelle Nanomaterials for Targeted Treatment of Ulcerative Colitis. J Biomed Nanotechnol 18: 120–31.
   PubMed Web of Science ®Google Scholar
• Zhou X , Chen Z. ( 2015). Preparation and performance evaluation of emulsomes as a drug delivery system for silybin. Arch Pharm Res 38: 2193–200.
   PubMed Web of Science ®Google Scholar
• Zu M , Ma Y , Cannup B , et al. ( 2021). Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv Drug Deliv Rev 176: 113887.
   PubMed Web of Science ®Google Scholar
• Zu M , Song H , Zhang J , et al. ( 2020). Lycium barbarum lipid-based edible nanoparticles protect against experimental colitis. Colloids Surf B Biointerfaces 187: 110747.
   PubMed Web of Science ®Google Scholar